Introduction
============

Cystic fibrosis (CF) is the most common, severe, autosomal recessive genetic disease in Caucasians. It is caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), a chloride channel expressed in epithelial cells throughout the body ([@B27]). The disease affects several organs such as the lungs, pancreas, intestine, and liver. Over 2,000 variations in the *CFTR* gene have been described, including 312 CF-causing variant \[The Clinical and Functional TRanslation of CFTR (CFTR2)^[1](#fn01){ref-type="fn"}^\], which are usually classified into six classes, according to their resulting effect on the protein ([@B9]). The most common mutation (70% of alleles) is p.Phe508del (F508del), which prevents normal CFTR expression at the apical surface of epithelia. *CFTR* genotype strongly influences pancreatic function, which is either deficient (PI for pancreatic insufficiency), or normal (PS for pancreatic sufficiency). It is recognized that in the major part of cases, patients carrying two PI-associated severe *CFTR* mutations have a classical form of CF, whereas others have a milder form of disease associated with PS ([@B9]).

Until recently, treatment of CF was only symptomatic. However, in recent years, considerable efforts have led to the development of therapies that target the CFTR protein. Since 2012, patients carrying the *CFTR* gating mutation p.Gly551Asp (G551D) and who are older than 6 years can be treated with ivacaftor, a molecule called a potentiator, which targets CFTR directly to increase the probability of the channel being open ([@B33]). Significant clinical benefits of ivacaftor, such as gain of lung function and reduced number of pulmonary exacerbations, were initially observed in patients older than 12 years and carrying at least one G551D *CFTR* mutation ([@B26]). Subsequently, ivacaftor was approved for other *CFTR*-gating mutations: p.Gly1244Glu (G1244E), p.Gly1349Asp (G1349D), p.Gly178Arg (G178R), p.Gly551Ser (G551S), p.Ser1251Asn (S1251N), p.Ser1255Pro (S1255P), p.Ser549Asn (S549N), and p.Ser549Arg (S549R) ([@B12]) and younger patients ([@B11]). Now, ivacaftor is approved for patients with CF older than 2 years carrying at least one of these gating mutations ([@B10]).

The Solute Carrier Family 26 Member 9 gene, *SLC26A9*, was recently shown to modulate the airway response to CFTR-directed therapeutics. In particular, in CF patients carrying at least one CFTR-G551D mutation, the single nucleotide polymorphism (SNP), rs7512462, in the *SLC26A9* gene was shown to explain 28% of the response variability to ivacaftor ([@B29]). In that study, rs7512462 was also associated with the lung function variability of patients carrying a *CFTR*-gating mutation. Moreover, *SLC26A9* variants have been previously shown in genome wide association studies (GWAS) to contribute to the phenotype variability of meconium ileus ([@B30]) (rs7512462, rs4077468, rs4077469, rs7419153, rs12047830, rs12741299) and CF-related diabetes (CFRD, rs4077468, rs4077469, rs1874361) ([@B4]).

In the current study, we examine the French cohort (*n* = 4,840) of the French CF Gene Modifier Study to investigate whether *SLC26A9* variants firstly contribute to the variability of the lung phenotype, and secondly influence the response to ivacaftor.

Materials and Methods {#s1}
=====================

Study Subjects and Lung Phenotype
---------------------------------

Patients with CF treated in 38 out of the 47 French CF centres between January 2004 and January 2017 were enrolled in the French CF Modifier Gene Study. As of January 1, 2017, 4,840 patients with CF had been included (corresponding to ∼75% of all French patients with CF) ([@B32]). The study was approved by the French ethical committee (CPP n°2004/15), and the information collection was approved by the Commission Nationale de L'informatique et des Libertés (n°04.404). Informed consent in writing was obtained from each patient and/or guardian.

Measurements of the forced expiratory volume measured in 1 s (FEV~1~) were either expressed as percent-predicted values (FEV~1pp~) using the Global Lung Function Initiative (GLI) equations ([@B25]) or transformed to the Kulich Normalized Mortality Adjusted CF-specific lung phenotype (SaKnorm *Z*-value) ([@B14]; [@B31]). This quantitative phenotype allows indeed direct comparison of lung phenotypes between patients with CF and accounts for differential survival.

Details on the 4,840 CF patients are reported in **Table [1](#T1){ref-type="table"}** and in the Flowchart (**Figure [1](#F1){ref-type="fig"}**). Only patients with severe *CFTR* mutations were considered (pancreatic sufficient patients excluded). Among those, 119 carried at least one gating mutation for which ivacaftor therapy has been approved in Europe (i.e., G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, and S549R), 81 were prescribed ivacaftor. Finally, 60 patients on ivacaftor had lung function measurements available before and after treatment initiation. To assess the association of *SLC26A9* with lung function response to ivacaftor, we included the 30 patients older than 6 years of age and with FEV~1pp~ in the 3 months before treatment initiation ranging between 40 and 90%; their *CFTR* genotypes are depicted in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}. The response to treatment was determined by the change in FEV~1pp~ from baseline, averaged in the 15--75 days after treatment, as well as that averaged over the 1st-year post-treatment, as used in an earlier study (**Table [1](#T1){ref-type="table"}**) ([@B29]). Besides, these two timelines were chosen to evaluate: (1) an "early" response (15--75 days), as it takes several days for ivacaftor to reach a maximal response; and (2) a "long-term" response (1 year), computed by averaging the FEV~1pp~ over the 1st year of ivacaftor treatment, illustrating the overall response of the patients.

###### 

Baseline characteristics of the patients.

  Patient characteristics                 *CFTR* variants                 
  --------------------------------------- ----------------- ------------- -------------
  Pancreatic Insufficient (*n* = 4,045)   *n* = 2,143       *n* = 119     *n* = 72
  Sex (male/female)                       1,125/1018        64/55         42/30
  European origin, *n* (%)                2,061 (96)        105 (88)      67 (93)
  Treated by ivacaftor (*n* = 81)                                         
  FEV~1pp~ (baseline) ^\$^                                  *n* = 60      *n* = 40
  \>90%                                                     17            16
  40--90%                                                   30            16
  \<40%                                                     13            8
  FEV~1pp~ change analysis (*n* = 30)                       *n* = 30      *n* = 16
  Age, mean (*SD*)                                          20.0 (14.0)   17.6 (12.4)
  Sex (male/female)                                         18/12         10/6

\$

Ivacaftor-approved CFTR gating mutations: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, and S549R;

∗∗

FEV

1pp

(forced expiratory volume in 1 s percent-predicted) value in the 3 months before treatment. Data are means (SD) or numbers (%) unless otherwise indicated. CFTR: Cystic Fibrosis Transmembrane Conductance Regulator.

![Flowchart of the study.](fphar-09-00828-g001){#F1}

Genotyping
----------

The genotyping of *SLC26A9* SNPs (rs7512462, rs4077468, rs7419153, rs12047830, rs4077469, rs12741299, and rs1874361) was carried out using Kompetitive Allele Specific PCR (KASP) genotyping chemistry (LGC, Teddington, United Kingdom).

Statistical Analysis
--------------------

Lung function was analyzed as FEV~1pp~ (GLI) ([@B25]) or CF-specific quantile-Z value (SaKnorm *Z*-value) ([@B14]; [@B31]). For each patient, FEV~1pp~ measurements in the 15-75 days following treatment initiation were averaged to determine the early response. We used the trapezoidal rule to compute average FEV~1pp~ over the 1st year to account for irregular measurements. The change in FEV~1pp~ from baseline was then analyzed by linear regression, adjusting for baseline measurement. We used additive coding to estimate the effect of SNPs in *SLC26A9.* Reference alleles were taken from annotations of the human genome^[2](#fn02){ref-type="fn"}^. Among SNPs in *SLC26A9*, rs7512462 had previously shown association with treatment response and, therefore, was analyzed independently from the other SNPs. We also analyzed five other SNPs in *SLC26A9*, adjusting the *P*-values for multiplicity in this situation.

Conformance of the allele frequencies with the Hardy--Weinberg equilibrium (HWE) was tested using a Fisher's exact test. As shown in Supplementary Table [S2](#SM2){ref-type="supplementary-material"}, the population did not deviate significantly from the HWE indicating no issue with the genotyping method or population stratification.

We reconstructed haplotypes using the EM algorithm with all patients (*n* = 4,045) keeping loci in their physical order on chromosome 1 (using haplo.stats package in the R software) (Supplementary Table [S3](#SM3){ref-type="supplementary-material"}) ([@B15]). We analyzed the association of haplotypes with FEV~1pp~ using additive haplotype coding (see Supplementary Material).

A *P*-value of less than 5% was interpreted as evidence of a statistically significant difference or association. Multiple comparisons utilized the Bonferroni correction. All association analyses were carried out using the software, R (version 3.4.0^[3](#fn03){ref-type="fn"}^).

Results
=======

*SLC26A9* Gene Variants and Lung Function
-----------------------------------------

In the absence of ivacaftor treatment, the effect of rs7512462 on lung function did not reach statistical significance for any *CFTR* genotype group. We considered all patients (*n* = 3,418), F508del homozygous patients (*n* = 1,804), carriers of at least one ivacaftor-approved gating mutation (*n* = 93), and carriers of one G551D allele (*n* = 49) (**Figure [2](#F2){ref-type="fig"}** and **Table [2](#T2){ref-type="table"}**). The results were similar with other SNPs in the *SLC26A9* gene (i.e., rs1874361, rs12741299, rs4077468, rs4077469, rs12047830, rs7419153) (**Table [3](#T3){ref-type="table"}**).

![Lung phenotype distribution according to *SLC26A9* rs7512462 variant in patients with cystic fibrosis. Smoothed histograms of SaKnorm *Z*-values by *SLC26A9* rs7512462 genotypes (gray areas), genotype specific mean ± SE (dot and bars) and overall mean (dashed). **(A)** All pancreatic insufficient CF patients (*n* = 3,418), **(B)** *CFTR* F508del homozygous CF patients (*n* = 1,804), **(C)** CF patients with at least one G551D allele (*n* = 49) and **(D)** CF patients with at least one ivacaftor-approved gating mutation (*n* = 93).](fphar-09-00828-g002){#F2}

###### 

Mean differences in lung function according to *CFTR* and *SLC26A9* variants.

               All pancreatic insufficient   F508del/F508del   G551D/other     Gating^\$^/other                                          
  ------------ ----------------------------- ----------------- --------------- ------------------ --------------- ------ --------------- ------
  rs7512462    0.03 ± 0.02                   0.20              0.03 ± 0.03     0.29               0.14 ± 0.16     0.40   0.13 ± 0.12     0.27
  rs1874361    --0.02 ± 0.02                 0.30              --0.00 ± 0.03   0.97               --0.07 ± 0.16   0.66   --0.17 ± 0.11   0.13
  rs12741299   0.01 ± 0.03                   0.70              --0.02 ± 0.04   0.64               --0.06 ± 0.33   0.86   0.23 ± 0.23     0.32
  rs4077468    0.05 ± 0.02                   0.01              0.05 ± 0.03     0.07               0.22 ± 0.18     0.22   0.14 ± 0.13     0.29
  rs4077469    0.05 ± 0.02                   0.01              0.05 ± 0.03     0.08               0.22 ± 0.17     0.21   0.14 ± 0.13     0.26
  rs12047830   0.04 ± 0.02                   0.03              0.03 ± 0.02     0.19               0.37 ± 0.18     0.05   0.27 ± 0.13     0.05
  rs7419153    --0.02 ± 0.02                 0.359             --0.02 ± 0.03   0.47               --0.35 ± 0.18   0.06   --0.18 ± 0.14   0.20

\$

See description Supplementary Table

S2

;

\$

Ivacaftor-approved CFTR gating mutations: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, and S549R;

∗

change per minor allele (linear regression of SaKnorm Z-value with additive model). SaKnorm is normalized function of FEV

1

(forced expiratory volume in 1 s) adjusted for age, sex, height, and cohort-specific survival.

###### 

Change in lung function evolution after 15--75 days and after 1 year on ivacaftor.

                                                                  *n*   Before^∗∗^   After   Difference   95% CI        *P*-value^∗^
  --------------------------------------------------------------- ----- ------------ ------- ------------ ------------- --------------
  **Average FEV~1pp~ measures within 15--75 days on ivacaftor**                                                         
  Gating^\$^/other                                                23    66.13        80.85   11.72        7.32--16.06   \<0.0001
  G551D/other                                                     14    70.66        85.05   14.39        7.89--20.66   0.00012
  **Average FEV~1pp~ measures in the 1st year on ivacaftor**                                                            
  Gating^\$^/other                                                30    69.07        78.90   9.83         4.91--14.77   \<0.0001
  G551D/other                                                     16    69.14        84.2    15.06        7.10--23.14   \<0.0001

\$

Ivacaftor-approved CFTR gating mutations: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, and S549R;

∗∗

FEV

1pp

(forced expiratory volume in 1 s percent-predicted) value in the 3 months before treatment.

∗

Paired Mann--Whitney--Wilcoxon test.

Change in FEV~1~ With Ivacaftor
-------------------------------

In total, 30 pancreatic insufficient CF patients had at least one ivacaftor-approved gating mutation, baseline FEV~1pp~ between 40 and 90%, and post-treatment data (see Flowchart, **Figure [1](#F1){ref-type="fig"}**). FEV~1pp~ measurements within 15--75 days post-treatment and in the 1st year on ivacaftor were available for 23 and 30 patients, respectively, among whom 14 and 16, respectively, were carriers of at least one G551D allele (see Flowchart, **Figure [1](#F1){ref-type="fig"}**). Overall, patients showed an improvement in FEV~1pp~ after 15--75 days and in the 1st year on ivacaftor. For individuals with ivacaftor-approved gating mutations, the baseline-adjusted change in FEV~1pp~ was +11.72% (95% CI: 7.32--16.06) at 15--75 days and +9.83% (95% CI: 4.91--14.77) in the 1st year of treatment (*P* \< 0.0001, **Table [3](#T3){ref-type="table"}** and **Figure [3](#F3){ref-type="fig"}**). In patients with at least one G551D allele, the improvement in FEV~1pp~ was +14.39% (95% CI: 7.89--20.66) at 15--75 days and +15.06% (95% CI: 7.1--23.14) over the 1st year of treatment (*P* \< 0.0001, **Table [3](#T3){ref-type="table"}** and **Figure [3](#F3){ref-type="fig"}**).

![FEV~1pp~ change from baseline in patients carrying at least one ivacaftor-approved gating mutation (light blue) or one G551D variant (dark blue) within the first 15--75 days and over the 1st year of ivacaftor.](fphar-09-00828-g003){#F3}

*SLC26A9* Variants and Ivacaftor Treatment Response
---------------------------------------------------

In patients carrying at least one G551D allele, the response to treatment changed with the *SLC26A9* rs7512462 genotype, with less change in FEV~1pp~ (-7.7% over 15--75 days and -7.8% over 1 year of treatment) for each C allele (*P* = 0.0007 and 0.006, respectively; **Table [4](#T4){ref-type="table"}** and **Figure [4](#F4){ref-type="fig"}**). Other *SLC26A9* variants showed similar associations with the changes in FEV~1pp~. In particular, the following SNPs demonstrated significant association after adjustment for multiplicity: with reduced FEV~1pp~ over 15--75 days: rs4077468, -7.9 FEV~1pp~ (*P*~adj~ = 0.0007); and rs4077469, -9.3 FEV~1pp~ (*P*~adj~ = 0.0035); or with increased FEV~1pp~ over 15--75 days: rs7419153, +9.8 FEV~1pp~ (*P*~adj~ = 0.0049) (**Table [4](#T4){ref-type="table"}**).

###### 

Change in FEV~1pp~ within 15--75 days and over 1 year on ivacaftor treatment according to *SLC26A9* variants in patients carrying at least one G551D mutation.

  Period of evaluation   15--75 days after ivacaftor treatment start   Over the 1st year of ivacaftor treatment                                    
  ---------------------- --------------------------------------------- ------------------------------------------ -------- -------------- -------- --------
  rs7512462              --7.7 ± 1.7                                   0.0007                                     0.0049   --7.8 ± 2.4    0.0063   0.0441
  rs1874361              4.4 ± 1.5                                     0.0107                                     0.0749   3.1 ± 3.0      0.3129   1.0000
  rs12741299             2.9 ± 6.0                                     0.6336                                     1.0000   2.1 ± 5.9      0.7331   1.0000
  rs4077468              --7.9 ± 1.3                                   0.0001                                     0.0007   --8.4 ± 1.7    0.0003   0.0027
  rs4077469              --9.3 ± 1.9                                   0.0005                                     0.0035   --10.5 ± 2.3   0.0006   0.0042
  rs12047830             --10.9 ± 2.7                                  0.0020                                     0.014    --7.5 ± 3.5    0.0518   0.3626
  rs7419153              9.8 ± 2.1                                     0.0007                                     0.0049   8.1 ± 2.6      0.0089   0.0623

\$

See description Supplementary Table

S2

;

∗

linear regression of FEV

1pp

(forced expiratory volume in 1 s percent-predicted) change with additive model adjusted on baseline;

∗∗

Bonferroni adjustment.

![FEV~1pp~ change from baseline in patients with ivacaftor treatment according to rs7512462 *SLC26A9* genotype. Individual change in patients with at least one G551D mutation (blue) and with other gating mutations (red) and model fitted mean change (horizontal bar) within the first 15--75 days of treatment **(A)** and over the 1st year of treatment **(B)**.](fphar-09-00828-g004){#F4}

The results for individuals with gating mutations were similar. Indeed, the response to treatment also changed with the *SLC26A9* rs7512462 genotype, with less change in FEV~1pp~ (-5.9% over 15--75 days and -5.2% over 1 year of treatment) for each C allele (*P* = 0.0031 and 0.0042, respectively; **Table [5](#T5){ref-type="table"}** and **Figure [4](#F4){ref-type="fig"}**). Moreover, other *SLC26A9* variants also showed similar associations with, in particular, significant association after adjustment for multiplicity for the following SNPs with reduced FEV~1pp~ over 15--75 days: rs4077468, -7.0 FEV~1pp~ (*P*~adj~ = 0.0231); and rs4077469, -7.8 FEV~1pp~ (*P*~adj~ = 0.0490) (**Table [5](#T5){ref-type="table"}**).

###### 

Change in FEV~1pp~ within 15--75 days and over 1 year on ivacaftor treatment according to *SLC26A9* variants in patients carrying at least one ivacaftor-approved *CFTR* gating mutation.

  Period of evaluation   15--75 days after ivacaftor treatment start   Over the 1st year of ivacaftor treatment                                   
  ---------------------- --------------------------------------------- ------------------------------------------ -------- ------------- -------- --------
  rs7512462              --5.9 ± 1.7                                   0.0031                                     0.0217   --5.2 ± 1.8   0.0042   0.0294
  rs1874361              3.7 ± 1.3                                     0.0120                                     0.0840   3.9 ± 1.9     0.0479   0.3346
  rs12741299             --2.8 ± 4.8                                   0.5656                                     1.0000   --2.7 ± 4.2   0.5270   1.0000
  rs4077468              --7.0 ± 2.1                                   0.0033                                     0.0231   --7.3 ± 2.2   0.0030   0.0210
  rs4077469              --7.8 ± 2.6                                   0.0070                                     0.0490   --8.2 ± 2.6   0.0040   0.0280
  rs12047830             --6.3 ± 2.4                                   0.0138                                     0.0966   --6.6 ± 2.6   0.0161   0.1127
  rs7419153              6.3 ± 2.6                                     0.0233                                     0.1631   7.9 ± 2.5     0.0038   0.0266

\$

See description Supplementary Table

S2

;

∗

linear regression of FEV

1pp

(forced expiratory volume in one second percent-predicted) change with additive model adjusted on baseline;

∗∗

Bonferroni adjustment;

\$

Ivacaftor-approved CFTR gating mutations: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, and S549R.

In these patients, the most frequent haplotypes (7 SNPs in physical order, Supplementary Table [S2](#SM2){ref-type="supplementary-material"}) were CCCGTAG (35%) and TACACGA (18%) (Supplementary Table [S3](#SM3){ref-type="supplementary-material"}). In agreement with the direction of association in the SNP analysis, FEV~1pp~ in carriers of at least one CCCGTAG haplotype increased on average by 17 ± 12% over 15--75 days and by 17 ± 17% over 1 year of treatment, while the FEV~1pp~ of the carriers of at least one TACACGA increased by 6 ± 5% over 15--75 days and 4 ± 5% over 1 year of treatment. Overall, this analysis did not provide significant evidence for a heterogeneity in FEV~1pp~ change with haplotypes (*P* = 0.2 over 15--75 days, *P* = 0.08 over 1 year), but was underpowered given the large diversity of haplotypes in the sample (Supplementary Table [S3](#SM3){ref-type="supplementary-material"}).

Discussion
==========

We have shown that the response to ivacaftor measured as lung function modulation varied between individuals and is associated with *SLC26A9* variants, as previously described ([@B29]). *SLC26A9* is a key candidate in CF as it has been shown to play a pleiotropic role across CF phenotypes, associated with meconium ileus ([@B30]; [@B16]), immunoreactive trypsinogen at birth ([@B28]; [@B22]), pancreatic damage ([@B16]), and CFRD ([@B4]; [@B28]). With the development of new curative treatments, such as CFTR-targeted therapies, pharmacogenomics will become a major step toward functional personalized medicine ([@B9]).

*SLC26A9* Gene Modulates Ivacaftor Lung Response
------------------------------------------------

We observed that *SLC26A9* variants were associated with the variability in lung responses to ivacaftor measured as FEV~1pp~ change over 1 year with treatment. Indeed, we have shown that, although the response varied between individuals, FEV~1pp~ improved after 15--75 days to 1 year on ivacaftor, in agreement with several clinical trials that led to the approbation of this drug ([@B26]; [@B11], [@B10]; [@B12]; [@B21]). Further, we observed, as previously shown by [@B29], that *SLC26A9* variants modulate this drug response. Focusing on *SLC26A9* rs7512462 in the patients carrying at least one G551D *CFTR* mutation, we observed that the CC genotype was associated with a decrease in FEV~1pp~ of -7.7%. Surprisingly, this effect was inverse to that observed in the pilot study of [@B29] who showed an increase in FEV~1pp~ of approximately 8.5% for each additional C allele at rs7512462. Since rs7512462 is not presumed to be functional ([@B29]), it must be linked to the causal variants so that population-specific differences could explain this difference in direction. In fact, the North-American CF Gene Modifier consortium found significant population admixture in the North-American CF patients, with a large portion of patients reporting African--Caucasian, Mexican--Caucasian, and Indian--Caucasian ancestries ([@B17]), whereby French patients are predominantly of Caucasian origin. Besides, it has been found that the pharmacogenetic response to drugs varied across ethnic groups, which might play a role in the differences observed here between French and Canadian cohorts ([@B8]). Nevertheless, [@B29] observed in CF patients carrying at least one CFTR-G551D mutation, that the rs7512462 SNP in the *SLC26A9* gene explained 28% of the response variability to ivacaftor, a result similar to ours (22%) ([@B29]). We observed similar results when evaluating both G551D carriers and patients carrying other ivacaftor-approved gating mutations. There remains, however, a large part of interindividual variation besides the SNP status.

*SLC26A9* Gene Is Not a Modifier of Lung Function in CF Patients
----------------------------------------------------------------

In this study, *SLC26A9* variants were not associated with variation in lung function of French patients with CF, regardless of their *CFTR* genotype (i.e., two copies of the F508del mutation and/or at least one gating mutation, the most frequent being G551D). These results are in agreement with previous, large international GWAS studies ([@B34]; [@B7]). The latest and largest study, a meta-analysis of 6,365 French and North-American CF patients, identified five regions outside the *SLC26A9* locus that displayed significant association with variation in lung disease: the locus of the mucin genes *MUC4* and *MUC20*, of the solute carrier genes *SLC9A3* and *SLC6A14*, and of the HLA Class II region ([@B7]). No association was observed between lung function and the *SLC26A9* gene. In the pilot study of [@B29] *SLC26A9* rs7512462 also was not associated with lung function variation in CF patients who were homozygous for the F508del mutation. However, an association was observed for patients carrying at least one G551D variant, for whom the number of C alleles was positively associated with improved lung function ([@B29]). Another independent study of a smaller Brazilian CF cohort with various *CFTR* mutations also did not show an association of this variant with FEV~1~ heterogeneity ([@B24]). We tested other *SLC26A9* variants that had been previously shown in GWAS to contribute to the variability of other phenotypes, such as meconium ileus (rs4077468, rs4077469, rs7419153, rs12047830, rs12741299) ([@B30]) and CFRD (rs4077468, rs4077469, rs1874361) ([@B4]). However, we found that none of these variants contributed to the lung function heterogeneity in our CF cohort.

Mechanisms of SLC26A9 Variants to Modulate Ivacaftor Lung Response
------------------------------------------------------------------

SLC26A9 is a highly conserved protein predominantly expressed in the lung ([@B18]). It functions as a chloride channel with minimal bicarbonate conductance ([@B19]; [@B3]), and may constitute an attractive alternative ion channel strategy to compensate for the CFTR defect ([@B20]). Indeed, in human bronchial epithelial cells, it has been shown that SLC26A9 contributes to constitutive and cAMP-dependant chloride secretion ([@B3]; [@B1]). Physical interaction between SLC26A9 and CFTR has been shown in several studies ([@B3]; [@B5]; [@B1]), even if the consequences of this interaction \[reviewed in ([@B13])\] are still controversial. According to these studies, SLC26A9 interaction with CFTR enhances CFTR activity ([@B3]; [@B1]). Reciprocally, CFTR has been shown to modulate SLC26A9 function ([@B3]). However, there has also been evidence showing that CFTR inhibits the activity of SLC26A9 ([@B5]; [@B23]). More recently, SLC26A9 membrane expression and activity was shown to be decreased by CFTR-F508del in co-expression experiments using HEK cells. Interestingly, the correction of F508del CFTR by VX-809 (lumacaftor) was also shown to restore SLC26A9 activity ([@B2]). Finally, a previous functional analysis of eight non-synonymous coding SNPs (p.Y70N, p.T1247N, p.I384T, p.R575W, p.606L, p.V622L, p.V744M, and p.H748R) revealed several functional modifications, including increased or decreased channel activity and altered protein expression that could modify disease ([@B6]).

The exact mechanism explaining how *SLC26A9* variants affect the ivacaftor responses that we observed in our patients is unknown (depicted in **Figure [5](#F5){ref-type="fig"}**) and requires future investigation. Based on previous reports, it is reasonable to hypothesize that the variants have an impact on SLC26A9-CFTR-G551D interactions, which could result in altered intracellular trafficking of CFTR-G551D and/or transporter activation.

![Proposed mechanism of the modulation of ivacaftor lung response in CF patients by *SLC26A9* gene.](fphar-09-00828-g005){#F5}

Our study has several limitations, mainly related to the small sample size of the cohort treated with ivacaftor, due to the rarity of *CFTR* gating mutations (∼4% of individuals with CF). Moreover, baseline FEV~1~ measurements at ivacaftor treatment initiation was missing for about one third of the patients (see flowchart), which reduced even more the size of the analyzed cohort. Nevertheless, this study highlights that the interindividual variability in the lung response to ivacaftor might genetically be associated with *SLC26A9* variants in French CF patients and confirms the key pleiotropic role of this gene in CF. To confirm these results, it will be important to extend this study to patients with CF from different countries worldwide. The elucidation of the biological mechanisms beyond this variability is also necessary and will require functional genetic studies. In the exciting current era of curative treatment development in CF, pharmacogenomics will soon be an integral part of patient care, to modify treatment accordingly to provide the ultimate personalized medicine.
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